

# Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Meeting – April 12, 2023 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

**NOTE:** *The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.*

## **AGENDA**

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

### **1. Call to Order**

A. Roll Call – Dr. Wilcox

### **DUR Board Members:**

Dr. Jennifer de los Angeles –	participating in person
Mr. Kenneth Foster –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Lynn Mitchell –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person
Dr. Edna Patatanian –	participating in person

### **Viewing Access Only via Zoom:**

Please register for the meeting at:

[https://zoom.us/webinar/register/WN\\_73z8ERX7Sv-KeQGP3GVqPg](https://zoom.us/webinar/register/WN_73z8ERX7Sv-KeQGP3GVqPg)

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 952 7560 1667

Passcode: 69395211

## **Public Comment for Meeting:**

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at [www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board](http://www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board) and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to [DURPublicComment@okhca.org](mailto:DURPublicComment@okhca.org). Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

### **2. Public Comment Forum**

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

### **3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**

- A. March 8, 2023 DUR Board Meeting Minutes
- B. March 8, 2023 DUR Board Recommendations Memorandum

Items to be presented by Dr. Kottoor, Dr. Travers, Dr. Muchmore, Chairman:

### **4. Update on Medication Coverage Authorization Unit/SoonerPsych and Pediatric SoonerPsych Antipsychotic Monitoring Program Update – See Appendix B**

- A. Pharmacy Help Desk Activity for March 2023
- B. Medication Coverage Activity for March 2023
- C. SoonerPsych and Pediatric SoonerPsych Antipsychotic Monitoring Program Update

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

### **5. Action Item – Vote to Prior Authorize Briumvi™ (Ublituximab-xiiy) and Tascenso ODT® [Fingolimod Orally Disintegrating Tablet (ODT)] and Update the Approval Criteria for Multiple Sclerosis (MS) Medications – See Appendix C**

- A. Market News and Updates
- B. Briumvi™ (Ublituximab-xiiy) Product Summary
- C. Cost Comparison: Fingolimod Products
- D. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**6. Action Item – Vote to Prior Authorize Lamzede® (Velmanase Alfa) – See Appendix D**

- A. Lamzede® (Velmanase Alfa) Product Summary
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

**7. Action Item – Vote to Prior Authorize Rolvedon™ (Eflapegrastim-xnst) and Stimufend® (Pegfilgrastim-fpgk) and Update the Approval Criteria for the Granulocyte Colony-Stimulating Factors (G-CSFs) – See Appendix E**

- A. Market News and Updates
- B. Cost Comparison
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Kottoor, Dr. Muchmore, Chairman:

**8. Action Item – Vote to Prior Authorize Airsupra™ (Albuterol/Budesonide) – See Appendix F**

- A. Market News and Updates
- B. Airsupra™ (Albuterol/Budesonide) Inhalation Aerosol Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Reynolds, Dr. Muchmore, Chairman:

**9. Action Item – Vote to Prior Authorize Olpruva™ (Sodium Phenylbutyrate Pellets for Oral Suspension) and Pheburane® (Sodium Phenylbutyrate Oral Pellets) and Update the Approval Criteria for the Urea Cycle Disorder (UCD) Medications – See Appendix G**

- A. Market News and Updates
- B. Cost Comparison: UCD Medications
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**10. Action Item – Vote to Prior Authorize Jaypirca™ (Pirtobrutinib) and Lunsumio™ (Mosunetuzumab-axgb) and Update the Approval Criteria for the Lymphoma Medications– See Appendix H**

- A. Market News and Updates
- B. Jaypirca™ (Pirtobrutinib) Product Summary
- C. Lunsumio™ (Mosunetuzumab-axgb) Product Summary
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Reynolds, Dr. Muchmore, Chairman:

**11. Action Item – Annual Review of Hereditary Angioedema (HAE) Medications – See Appendix I**

- A. Current Prior Authorization Criteria
- B. Utilization of HAE Medications

- C. Prior Authorization of HAE Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of HAE Medications

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**12. Annual Review of Lung Cancer Medications and 30-Day Notice to Prior Authorize Krazati® (Adagrasib) and Imjudo® (Tremelimumab-actl) – See Appendix J**

- A. Current Prior Authorization Criteria
- B. Utilization of Lung Cancer Medications
- C. Prior Authorization of Lung Cancer Medications
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Lung Cancer Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**13. Annual Review of Anti-Diabetic Medications and Kerendia® (Finerenone) and 30-Day Notice to Prior Authorize Brenzavvy™ (Bexagliflozin), Mounjaro® (Tirzepatide), and Tzield™ (Teplizumab-mzwv) – See Appendix K**

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Diabetic Medications and Kerendia® (Finerenone)
- C. Prior Authorization of Anti-Diabetic Medications and Kerendia® (Finerenone)
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Anti-Diabetic Medications and Kerendia® (Finerenone)

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

**14. 30-Day Notice to Prior Authorize Syfovre™ (Pegcetacoplan) – See Appendix L**

- A. Introduction
- B. Syfovre™ (Pegcetacoplan) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**15. 30-Day Notice to Prior Authorize Skyclarys™ (Omaveloxolone) – See Appendix M**

- A. Introduction
- B. Skyclarys™ (Omaveloxolone) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Reynolds, Dr. Muchmore, Chairman:

**16. Annual Review of Systemic Antifungal Medications and 30-Day Notice to Prior Authorize Ancobon® (Flucytosine) and Vivjoa® (Oteseconazole) – See Appendix N**

- A. Current Prior Authorization Criteria
- B. Utilization of Systemic Antifungal Medications
- C. Prior Authorization of Systemic Antifungal Medications
- D. Market News and Updates
- E. Vivjoa® (Oteseconazole) Product Summary
- F. Cost Comparison: Recurrent Vulvovaginal Candidiasis (RVVC) Treatments
- G. College of Pharmacy Recommendations
- H. Utilization Details of Antifungal Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**17. Annual Review of Anti-Ulcer Medications and 30-Day Notice to Prior Authorize Konvomep™ (Omeprazole/Sodium Bicarbonate) – See Appendix O**

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Ulcer Medications
- C. Prior Authorization of Anti-Ulcer Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Anti-Ulcer Medications

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

**18. 30-Day Notice to Prior Authorize Filspari™ (Sparsentan) – See Appendix P**

- A. Introduction
- B. Filspari™ (Sparsentan) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Kottoor, Dr. Muchmore, Chairman:

**19. Annual Review of Insomnia Medications and 30-Day Notice to Prior Authorize Doral® (Quazepam) – See Appendix Q**

- A. Current Prior Authorization Criteria
- B. Utilization of Insomnia Medications
- C. Prior Authorization of Insomnia Medications
- D. Market News and Updates
- E. Doral® (Quazepam) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Insomnia Medications

Items to be presented by Dr. Kottoor, Dr. Muchmore, Chairman:

**20. Annual Review of Lumizyme® (Alglucosidase Alfa) and Nexviazyme® (Avalglucosidase Alfa-ngpt) – See Appendix R**

- A. Current Prior Authorization Criteria
- B. Utilization of Lumizyme® (Alglucosidase Alfa) and Nexviazyme® (Avalglucosidase Alfa-ngpt)
- C. Prior Authorization of Lumizyme® (Alglucosidase Alfa) and Nexviazyme® (Avalglucosidase Alfa-ngpt)
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Lumizyme® (Alglucosidase Alfa) and Nexviazyme® (Avalglucosidase Alfa-ngpt)

Items to be presented by Dr. Kottoor, Dr. Muchmore, Chairman:

**21. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix S**

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

**22.Future Business\* (Upcoming Product and Class Reviews)  
No DUR Board meeting scheduled for May 2023.**

- A. Annual Review of the SoonerCare Pharmacy Benefit
- B. Attention-Deficit/Hyperactivity Disorder (ADHD) and Narcolepsy Medications
- C. Atypical Antipsychotic Medications
- D. Hemophilia Medications

\*Future product and class reviews subject to change.

**23.Adjournment**

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.